Drug · CHEMBL407

FLUMAZENIL

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. FLUMAZENIL. Drugs and targets, record CHEMBL407. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL407

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: FLUMAZENIL; ChEMBL
ChEMBL ID: CHEMBL407; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Anexate, Romazicon; ChEMBL
Other names: Flumazepil, Lanexat, Mazicon, NSC-759193, RO 15-1788/000, RO-15-1788, RO-15-1788/000, RO-151788, RO-151788000, RO-1722, RO-41-8157; ChEMBL
DrugBank: DB01205; DrugBank
InChIKey: OFBIFZUFASYYRE-UHFFFAOYSA-N; ChEMBL
Open Targets' highest stage: Approval, as Open Targets' drug record gives it; Open Targets

Targets16

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
GABRA1	GABA-A receptor; anion channel	GABA-A receptor; anion channel allosteric antagonist	ALLOSTERIC ANTAGONIST	https://conductscience.org/library/genes/2554
GABRA2	GABA-A receptor; anion channel	GABA-A receptor; anion channel allosteric antagonist	ALLOSTERIC ANTAGONIST	https://conductscience.org/library/genes/2555
GABRA3	GABA-A receptor; anion channel	GABA-A receptor; anion channel allosteric antagonist	ALLOSTERIC ANTAGONIST	https://conductscience.org/library/genes/2556
GABRA4	GABA-A receptor; anion channel	GABA-A receptor; anion channel allosteric antagonist	ALLOSTERIC ANTAGONIST	https://conductscience.org/library/genes/2557
GABRA5	GABA-A receptor; anion channel	GABA-A receptor; anion channel allosteric antagonist	ALLOSTERIC ANTAGONIST	https://conductscience.org/library/genes/2558
GABRA6	GABA-A receptor; anion channel	GABA-A receptor; anion channel allosteric antagonist	ALLOSTERIC ANTAGONIST	https://conductscience.org/library/genes/2559
GABRB1	GABA-A receptor; anion channel	GABA-A receptor; anion channel allosteric antagonist	ALLOSTERIC ANTAGONIST	https://conductscience.org/library/genes/2560
GABRB2	GABA-A receptor; anion channel	GABA-A receptor; anion channel allosteric antagonist	ALLOSTERIC ANTAGONIST	https://conductscience.org/library/genes/2561
GABRB3	GABA-A receptor; anion channel	GABA-A receptor; anion channel allosteric antagonist	ALLOSTERIC ANTAGONIST	https://conductscience.org/library/genes/2562
GABRD	GABA-A receptor; anion channel	GABA-A receptor; anion channel allosteric antagonist	ALLOSTERIC ANTAGONIST	https://conductscience.org/library/genes/2563

1 to 10 of 16Source ChEMBL

See all 16 targets

Diseases10

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
alcohol dependence	Phase 2/3	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0007079
sedation	Unknown	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=EFO_0009868
Parkinson disease	Phase 1/2	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0005180
Respiratory distress	Unknown	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=HP_0002098
alcohol withdrawal	Phase 2/3	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0005433
atrial fibrillation	Unknown	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0004981
breast cancer	Unknown	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0007254
hypersomnia	Phase 1/2	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0005466
obsessive-compulsive disorder	Phase 2	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0008114
post operative nausea and vomiting	Phase 1	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=EFO_0004888

Source Open Targets

Trials35

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT00262639	Prometa Protocol for Alcohol Dependence	Phase 2/3	60	2009-08-14	flumazenil	Its name	ClinicalTrials.gov
NCT03462641	Modulation of GABA-A Receptors in Parkinson Disease-Flumazenil Arm	Phase 1/2	36	2022-06-29	flumazenil	Its name	ClinicalTrials.gov
NCT03440112	Modulation of GABA-A Receptors in Parkinson Disease-Transdermal Flumazenil Arm	Phase 1/2	34	2023-01-10	flumazenil	Its name	ClinicalTrials.gov
NCT02899156	Flumazenil for Hypoactive Delirium Secondary to Benzodiazepine Exposure	Phase 4	22	2020-07-23	flumazenil	Its name	ClinicalTrials.gov
NCT01183312	Flumazenil for the Treatment of Primary Hypersomnia	Phase 1/2	10	2013-03-27	flumazenil	Its name	ClinicalTrials.gov
NCT05382806	Reversal of Remimazolam by a Single Dose of Flumazenil		224		flumazenil	Its name	ClinicalTrials.gov
NCT07265050	Comparison of Emergence Agitation Between Remimazolam With Flumazenil and Propofol-based Total Intravenous Anesthesia in Patients Undergoing Nasal Surgery		204		flumazenil	Its name	ClinicalTrials.gov
NCT07277881	The Effect of Reversal of Remimazolam Sedation With Flumazenil on Cognitive Function in Patients Undergoing Hip Arthroplasty Under Spinal Anesthesia	Phase 4	150		flumazenil	Its name	ClinicalTrials.gov
NCT06513923	Comparison of Remimazolam and Propofol on Emergence in Elderly Orthopedic Patients Under General Anesthesia	Phase 4	136		flumazenil	Its name	ClinicalTrials.gov
NCT00260481	Prometa Pharmacotherapy for Methamphetamine Dependence	Phase 2/3	120		flumazenil	Its name	ClinicalTrials.gov

1 to 10 of 35

See all 35 trials

Comparisons in its trials7

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Flumazenil Treatment vs Placebo Treatment: deaths from any cause	0 of 28	0 of 29	57	NCT03462641	Trial comparisons
Flumazenil Treatment vs Placebo Treatment: serious adverse events	0 of 28	0 of 29	57	NCT03462641	Trial comparisons
Flumazenil Group vs Placebo Group: deaths from any cause	1 of 11	0 of 11	22	NCT02899156	Trial comparisons
Flumazenil Group vs Placebo Group: serious adverse events	0 of 11	0 of 11	22	NCT02899156	Trial comparisons
Sublingual Flumazenil vs Placebo: serious adverse events	0 of 10	0 of 10	20	NCT01183312	Trial comparisons
Flumazenil Group vs Placebo Group: Occurrence of Agitation Requiring Use of Rescue Sedatives While on Study Infusion	0 of 10	0 of 10	20	NCT02899156	Trial comparisons
Flumazenil Group vs Placebo Group: Number of Participants With Delirium Resolution	9 of 10	7 of 10	20	NCT02899156	Trial comparisons

Papers from its trials9

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
21631542	RESULT	1	PubMed
19593171	RESULT	1	PubMed
42802645	DERIVED	2	PubMed
38831029	DERIVED	1	PubMed
38205822	DERIVED	1	PubMed
37131126	DERIVED	1	PubMed
36229188	DERIVED	1	PubMed
28013354	DERIVED	2	PubMed
22082089	DERIVED	1	PubMed

Tests in its trials8

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	As a primary outcome	Source
Cancellation Test	1	1	ConductCognition
Continuous Performance Test	1	1	ConductCognition
Digit Span Test	1	1	ConductCognition
Psychomotor Vigilance Task	1	1	ConductCognition
Symbol Scan Task	1	1	ConductCognition
Trail Making Test A	1	1	ConductCognition
Trail Making Test B	1	1	ConductCognition
Verbal Learning	1	1	ConductCognition

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL407

GET https://conductscience.org/api/drugs/v1/CHEMBL407/trials?page=2

API reference For AI assistants